Monday, July 25, 2016

BRIEF-KaloBios begins early stage study of leukemia treatment

* KaloBios announces first patient dosed in phase 1 study of

Lenzilumab for the treatment of chronic myelomonocytic leukemia

Source text for Eikon:

Further company coverage:

(Bengaluru Newsroom: +1-646-223-8780)

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)